Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of Anti-CD19 CAR-Engineered NK Cells for Relapsed/Refractory B-cell Malignancies: a Multi-center, Open-label, Single-arm Clinical Study

NCT05410041 is registered in ClinicalTrials.gov with Beijing Boren Hospital as lead sponsor.

NCT NCT05410041
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05410041 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of Anti-CD19 CAR-Engineered NK Cells for Relapsed/Refractory B-cell Malignancies: a Multi-center, Open-label, Single-arm Clinical Study
Lead sponsor
Beijing Boren Hospital
Phase
Phase 1
Overall status
Unknown status
Start date
May 25, 2022
Completion date
May 31, 2024
Enrollment
15 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphocytic leukemia, chronic lymphocytic leukemia, non hodgkin lymphoma